SlideShare a Scribd company logo
DETECTION, REPORTING AND
MONITORING OF ADRs
DR SABEENA K CHOUDHARY
Overview
ā€¢ ADRs ( types and importance)
ā€¢ ADR Reporting (Pharmacovigilance): what
when and how to report these ADRs
History
ā€¢ Everytime we give a drug we take a risk
ā€¢ Public and professional concern about
these matters first arose in the late 19th
century.
ā€¢ In 1922, there was an enquiry into the
JAUNDICE associated with the use of
SALVARSAN, an organic arsenical used in
the treatment of Syphillis.
ā€¢ In 1937 in USA,
107 people died from taking
an Elixir Of Sulfalinamide
that contained the Solvent
Di-ethylene Glycol
This led to establishment of FOOD AND DRUG
ADMINISTRATION (FDA), which was given the task
of enquiring into the safety of new drugs before
allowing them to be marketed
ā€¢ In 1961, it was reported in West Germany that
there was an outbreak of PHOCOMELIA
(hypoplastic and aplastic limb deformities) in
the new born babies.
ā€¢ The Thalidomide Incident led to
development of a much more
sophisticated approach to preclinical
testing & clinical evaluation of drugs
before marketing, & greatly increased
awareness of adverse effect of drugs and
methods of detecting them.
Importance of ADRā€™S in
Therapeutics
Adverse event
ā€¢ Any untoward medical occurrence that may
present during treatment with a
pharmaceutical product
ā€¢ But doesnā€™t have a causal relation with this Rx
Adverse drug reaction
ā€¢ Response which is noxious and unintended ,
which occurs at doses normally used in
humans for the Px, Dx or therapy of the
disease or for modification of physiological
function
ā€¢ All ADR are AE but not vice versa
Side effect
ā€¢ Any unintended effect (unwanted but unavoidable of a product
occurring at normal dose which is related to the pharmacological
properties of the drug )
Unwanted but often unavoidable pharmacodynamic effects of a drug at
therapeutic dosesā€
As Extension of therapeutic effect
Atropine - dry mouth
As distinctly different effect
Promethazine ā€“ Sedation.
Side effect exploited for therapeutic use
Codeine ā€“ Diarrhoea
ADR vs side effect
Serious ADR
ā€¢ Death
ā€¢ Life threatening condition
ā€¢ Requires inpatient hospitalization/ prolongation
ā€¢ Persistent disability/incapacity
ā€¢ Congenital abnormality
Incidence
ļƒ˜Hospital in-patients:10-20%
ļƒ˜Deaths in hospital in-patients: 0.3-3%
ļƒ˜Hospital admissions: 0.3-5%
Why incidence is more ?
ā€¢ Ever-increasing number of new drugs in
the market
ā€¢ Number of drugs prescribed are high
ā€¢ Medication errors
ā€¢ Lack of awareness of a system for
reporting ADRā€™S
Common causes
ļ± Failing to take the correct dose at the correct times
ļ±Overdosing
ļ± Allergies to chemical components of the medicine
ļ± Combining the medicine with alcohol
ļ± Taking other drugs or preparations that interact with
the medicine
Factors affecting Adverse Drug
Reactions
ļ¶ Age
ļ¶ Genetic influences
ļ¶ Concurrent diseases (Renal, Liver, Cardiac)
ļ¶ Previous allergies or adverse drug reactions
ļ¶ Compliance with dosing regimen
ļ¶ Total number of medications
ļ¶ Misc. (diet, smoking, environmental
exposure)
Idiosyncracy
Idiosyncracy
ā€¢ Genetically determined abnormal reaction to
the agent
ā€¢ Interaction of the drug with the unique
feature of the individual
ā€¢ Produces uncharacteristic reaction
Types of ADRā€™s
Rawlins and Thompson classification -1991
Type A Predictable
-More Common(80%)
-Augmented normal
response
-Dose dependent
-Hypo/Hyper response
Type B Unpredictable
-Less common (6-10%)
-Abnormal/bizarre
response
-Dose Independent
-Genetic/Immunological
Type A Predictable
-Low Mortality
-d/t Pharmacological activity
of drug
-Rx : Dose Adjustment
Eg., S/E, Toxic effect,
Withdrawal effect
Diarrhea due to antibiotics
Type B Unpredictable
-High Mortality
-d/t Patient peculiarities
-Rx : Withdrawal of drug
Eg., Allergy, Idiosyncrasy
Hypersensitivity to
penicillin
Types of ADRā€™s ā€“ Contdā€¦
Type C (Chronic)
- Reactions due to prolonged use of the
Drug.
e.g. HPA axis suppression by corticosteroids
Type D (Delayed)
ā€¢ Occuring years after the treatment
ā€¢ Can be due to accumulation
E.g : Teratogenisis
Type E (End of use)
ā€¢ Occur on withdrawal especially when drug
is stopped abruptly
E.g.
ā€¢ Steroid withdrwal
Type F (Failure of drug)
ā€¢ Underdosing of medications
ā€¢ Drug interactions
Eg: OCP failure
Type Mnemonic Example
A Augmented Diarrohea due to antibiotics
B Bizzare Hypersensitivity due to
penicillin
C Chronic Steroid decrease HPA axis
D Delayed Teratogenicity, carcinogenesis
E End of use Precipitation of MI by Ī²
blocker withdrawal
F Failure OCP failure
Types of ADRā€™s in Brief:
Mild No need of Rx, antidote or Hospitalization
Moderate Requires drug change specific
Rx, hospitalization
Severe Potentially life threatening; permanent
damage, and prolonged hospitalization.
Lethal Directly or indirectly leads to
death
ADR GRADING
How to recognize an ADR
Who can get an ADR?
Anyone who takes medicine
Differential diagnosis should include
the possibility of an ADR if the
patient is taking any form of
medication
If symptoms,
ļƒ¼Appears soon after a new drug is
started
ļƒ¼Appears after an increase in dose
ļƒ¼Disappears when the drug is stopped
ļƒ¼Reappears when a drug is restarted
When To Report :
ADR Reporting System
ā€¢ WHO international system(Uppsala
monitoring centre, Sweden)
ā€¢ US FDA "Med watch"
ā€¢ UK "Yellow card system"
ā€¢ PvPI under CDSCO, India
ā€¢ ACTIVE SURVEILLANCE
ā€¢ PASSIVE SURVEILLANCE
ā€¢ SPONTANEOUS REPORTING SYSTEM :
ā€¢ Communication by HCP/ consumers/ pharma
company to NCC/CDSCO/AMC
Why is ADR Monitoring Needed?
ā€¢ Unreliability of pre-clinical studies
ā€¢ Limitations of pre-marketing phases of clinical trial
ā€¢ Aggressive marketing strategies of pharmaceutical companies
Limitations of pre-marketing phases of clinical
trial
ā€¢ Conducted in strictly controlled conditions, in highly
selected and limited number of patients
ā€¢ Fails to detect rare and delayed ADRs
ā€¢ Do not provide data ā€“
- In children, elderly patients, pregnant/lactating
women
- In patient suffering from other disease
- In patient receiving other drugs
- On interpopulation difference
What to report
ā€¢ All types of suspected ADRs irrespective of
whether they r known / uk, serious or non
serious , frequent or rare, and regardless of an
established causal relationship
ā€¢ Pharma meds and vaccines, drugs used in
traditional meds , medical devices, contrast
media
ā€¢ Any AE
ā€¢ Doctors
ā€¢ Dentists
ā€¢ Nurses
ā€¢ Pharmacists
Health care
professionals
ā€¢ Patients
ā€¢ Consumers
ā€¢ Relatives
Others
Who can report ??
Problems in ADR reporting
Patient Related
(i) Cannot recognize ADR
(ii) Recognize but do not
report
(iii) Illiteracy
Health professional
Related
(i) Cannot recognize ADR
(ii) Recognize but do not report due
to
- Lack of time
- Hesitancy
- Ignorance
- Fear of litigation
- Guilt
ā€¢
HOW TO REPORT??
Patient related information
Suspected adr
Suspected medications
Causality Assessment
ā€¢ Routine procedure in Pharmacovigilance
ā€¢ Relationship of cause & effect
ā€¢ Most outcomes : multiple interacting causes
ā€¢ Aim : to define contribution due to drugs
ā€¢ Problems:
ADRs rarely specific
Diagnostic tests usually absent
Re challenge rarely ethically justified
Causality Assessment Methods
Algorithmic:
Series of questions
Answers are weighted
Overall score determines causality category
e.g. Naranjoā€™s scale
Probalistic:
Set of explicitly defined causality categories
e.g. WHO UMC method
Questions Yes No Donā€™t
Know
1) Are there previous conclusive reports on this reaction? +1 0 0
2) Did the ADR appear after the suspected drug was
administered?
+2 -1 0
3) Did the ADR improve when the drug was discontinued? +1 0 0
4) Did the ADR appear with re-challenge? +2 -1 0
5) Are there alternative causes for the ADR? -1 +2 0
6) Did the reaction appear when placebo was given? -1 +1 0
7) Was the drug detected in blood at toxic levels? +1 0 0
8) Was the reaction more severe when the dose was
increased, or less severe when the dose was decreased?
+1 0 0
9) Did the patient have a similar reaction to the same or
similar drug in any previous exposure?
+1 0 0
10) Was the ADR confirmed by any objective evidence? +1 0 0
The Naranjo Probability Scale
The score :-
ā‰„ 9 = Definite
5-8 = Probable
1-4 = Possible
0 = Doubtful
Actions taken
Drugs restricted due to adverse
reactions
Drug Year Adverse Reaction Outcome
Sulfanilamide 1937 Liver damage due to
diethylene glycol
Solvent changed;
FDA established
Thalidomide 1961 Congenital
Malformations
Withdrawn
Chloramphenicol 1966 Blood Dyscrasias Uses restricted
Benoxaprofan 1982 Liver damage Withdrawn
Aspirin 1986 Reyeā€™s syndrome Uses restricted
Flecainide 1989 Cardiac Arrhythmias Uses restricted
Noscapine 1991 Gene toxicity Withdrawn
Triazolam 1991 Psychiatric disorders Withdrawn
Drug Year Adverse reaction Outcome
Temafloxacin 1992 Various serious
adverse effects
Withdrawn
Co-trimoxazole 1995 Serious allergic
reactions
Uses restricted
Terfenadine 1997 Interactions
(e.g. with
grapefruit juice)
Withdrawn
from OTC sale
Sotalol 1997 Cardiac
arrhythmias
Uses restricted
Astemizole 1998 Interactions Withdrawn
Cisapride 2000 Cardiac
arrhythmias
Withdrawn
Cerivastatin 2001 Rhabdomylosis Withdrawn
Drug Event Outcome
Fenfluramine,
Dexfenfluramine
Heart valve disease, Pulmonary
hypertension, Cardiac fibrosis
Banned
Sibutramine Heart attack , Stroke Banned
Astemizole ,Terfinadine Arrhythmias Banned
Rofecoxib ,Valdecoxib Myocardial infarction Banned
Rosiglitazone MI, stroke,CHF,death Banned
Cisapride QT interval prolongation- ventricular
arrhythmias
Banned
Gatifloxacin Arrhythmias, Phototoxicity,
Unpredictable hypoglycemia
Banned
Nimesulide (Paediatric) Fulminant hepatic failure Paediatric use -banned
Phenylpropanolamine Hemorrhagic stroke
Psychiatric disturbances
Banned( Banned order under
court stay)
Take home messageā€¦
ā€¢ Every drug which has an effect has an adverse effect every
time a drug is given risk is involved
ā€¢ For rational use of drug not only its clinical indications are
important but the knowledge of adverse effects as well
ā€¢ Early detection of adverse effects and its proper
management can be life saving in many situations
ā€¢ ADR Reporting (Pharmacovigilance) plays a important
role in the evolution and life history of a drug
Detection, reporting and monitoring of ad rs final ppt
Detection, reporting and monitoring of ad rs final ppt

More Related Content

What's hot

ICH Guidelines for Pharmacovigilance
ICH Guidelines for PharmacovigilanceICH Guidelines for Pharmacovigilance
ICH Guidelines for Pharmacovigilance
Dr. Ramesh Bhandari
Ā 
Pharmacovigilance programme of india
Pharmacovigilance programme of indiaPharmacovigilance programme of india
Pharmacovigilance programme of india
chandan kumar
Ā 
Severity, seriousness, predictability and preventability assessment
Severity, seriousness, predictability and preventability assessmentSeverity, seriousness, predictability and preventability assessment
Severity, seriousness, predictability and preventability assessment
Dr. Ramesh Bhandari
Ā 
Causality assessment,methods,pharmacovigilance
Causality assessment,methods,pharmacovigilanceCausality assessment,methods,pharmacovigilance
Causality assessment,methods,pharmacovigilance
Gaurav Chhabra
Ā 
Prescription event monitoring
Prescription event monitoringPrescription event monitoring
Prescription event monitoring
Reyaz Bhat
Ā 
Adverse drug reaction monitoring and reporting
Adverse drug reaction monitoring and reportingAdverse drug reaction monitoring and reporting
Adverse drug reaction monitoring and reporting
THUSHARA MOHAN
Ā 
Causality Assessment in Pharmacovigilance
Causality Assessment in PharmacovigilanceCausality Assessment in Pharmacovigilance
Causality Assessment in Pharmacovigilance
ClinosolIndia
Ā 
Good Clinical Practice and Pharmacovigilance
Good Clinical Practice and PharmacovigilanceGood Clinical Practice and Pharmacovigilance
Good Clinical Practice and Pharmacovigilance
Md. Zakaria Faruki
Ā 
Establishing Pharmacovigilance Centres In Hospital.pptx
Establishing Pharmacovigilance Centres In Hospital.pptxEstablishing Pharmacovigilance Centres In Hospital.pptx
Establishing Pharmacovigilance Centres In Hospital.pptx
RushikeshTidake
Ā 
Vaccine Safety Monitoring: Pharmacovigilance Strategies
Vaccine Safety Monitoring: Pharmacovigilance StrategiesVaccine Safety Monitoring: Pharmacovigilance Strategies
Vaccine Safety Monitoring: Pharmacovigilance Strategies
ClinosolIndia
Ā 
Ppt On National Programmes Related to Pharmacovigilance
Ppt On National Programmes  Related to PharmacovigilancePpt On National Programmes  Related to Pharmacovigilance
Ppt On National Programmes Related to Pharmacovigilance
Naveen K L
Ā 
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
 INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC) INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
Turacoz Skill Development Program
Ā 
INVESTIGATORā€™S BROCHURE (IB)
 INVESTIGATORā€™S BROCHURE (IB) INVESTIGATORā€™S BROCHURE (IB)
INVESTIGATORā€™S BROCHURE (IB)
SachinFartade
Ā 
Spontenous adr reporting
Spontenous adr reportingSpontenous adr reporting
Spontenous adr reporting
SONALPANDE5
Ā 
Designing of clinical study documentation -protocol and crf
Designing of clinical study documentation -protocol and crfDesigning of clinical study documentation -protocol and crf
Designing of clinical study documentation -protocol and crf
Rumana Hameed
Ā 
Drug information and poison information
Drug information and poison informationDrug information and poison information
Drug information and poison information
THUSHARA MOHAN
Ā 
Adverse drug reactions attributed to genetic differences
Adverse drug reactions attributed to genetic differences Adverse drug reactions attributed to genetic differences
Adverse drug reactions attributed to genetic differences
Ayesha Younas
Ā 
Budget preparation and implementation
Budget preparation and implementationBudget preparation and implementation
Budget preparation and implementation
Snehal Darekar
Ā 
Basic terminologies used in pharmacovigilance.pptx
Basic terminologies used in pharmacovigilance.pptxBasic terminologies used in pharmacovigilance.pptx
Basic terminologies used in pharmacovigilance.pptx
ReshmaManeDeshmukh
Ā 
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADRā€™S
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADRā€™SSEVERITY AND SERIOUSNESS ASSESSMENT OF ADRā€™S
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADRā€™S
Raghavendra institute of pharmaceutical education and research .
Ā 

What's hot (20)

ICH Guidelines for Pharmacovigilance
ICH Guidelines for PharmacovigilanceICH Guidelines for Pharmacovigilance
ICH Guidelines for Pharmacovigilance
Ā 
Pharmacovigilance programme of india
Pharmacovigilance programme of indiaPharmacovigilance programme of india
Pharmacovigilance programme of india
Ā 
Severity, seriousness, predictability and preventability assessment
Severity, seriousness, predictability and preventability assessmentSeverity, seriousness, predictability and preventability assessment
Severity, seriousness, predictability and preventability assessment
Ā 
Causality assessment,methods,pharmacovigilance
Causality assessment,methods,pharmacovigilanceCausality assessment,methods,pharmacovigilance
Causality assessment,methods,pharmacovigilance
Ā 
Prescription event monitoring
Prescription event monitoringPrescription event monitoring
Prescription event monitoring
Ā 
Adverse drug reaction monitoring and reporting
Adverse drug reaction monitoring and reportingAdverse drug reaction monitoring and reporting
Adverse drug reaction monitoring and reporting
Ā 
Causality Assessment in Pharmacovigilance
Causality Assessment in PharmacovigilanceCausality Assessment in Pharmacovigilance
Causality Assessment in Pharmacovigilance
Ā 
Good Clinical Practice and Pharmacovigilance
Good Clinical Practice and PharmacovigilanceGood Clinical Practice and Pharmacovigilance
Good Clinical Practice and Pharmacovigilance
Ā 
Establishing Pharmacovigilance Centres In Hospital.pptx
Establishing Pharmacovigilance Centres In Hospital.pptxEstablishing Pharmacovigilance Centres In Hospital.pptx
Establishing Pharmacovigilance Centres In Hospital.pptx
Ā 
Vaccine Safety Monitoring: Pharmacovigilance Strategies
Vaccine Safety Monitoring: Pharmacovigilance StrategiesVaccine Safety Monitoring: Pharmacovigilance Strategies
Vaccine Safety Monitoring: Pharmacovigilance Strategies
Ā 
Ppt On National Programmes Related to Pharmacovigilance
Ppt On National Programmes  Related to PharmacovigilancePpt On National Programmes  Related to Pharmacovigilance
Ppt On National Programmes Related to Pharmacovigilance
Ā 
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
 INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC) INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
Ā 
INVESTIGATORā€™S BROCHURE (IB)
 INVESTIGATORā€™S BROCHURE (IB) INVESTIGATORā€™S BROCHURE (IB)
INVESTIGATORā€™S BROCHURE (IB)
Ā 
Spontenous adr reporting
Spontenous adr reportingSpontenous adr reporting
Spontenous adr reporting
Ā 
Designing of clinical study documentation -protocol and crf
Designing of clinical study documentation -protocol and crfDesigning of clinical study documentation -protocol and crf
Designing of clinical study documentation -protocol and crf
Ā 
Drug information and poison information
Drug information and poison informationDrug information and poison information
Drug information and poison information
Ā 
Adverse drug reactions attributed to genetic differences
Adverse drug reactions attributed to genetic differences Adverse drug reactions attributed to genetic differences
Adverse drug reactions attributed to genetic differences
Ā 
Budget preparation and implementation
Budget preparation and implementationBudget preparation and implementation
Budget preparation and implementation
Ā 
Basic terminologies used in pharmacovigilance.pptx
Basic terminologies used in pharmacovigilance.pptxBasic terminologies used in pharmacovigilance.pptx
Basic terminologies used in pharmacovigilance.pptx
Ā 
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADRā€™S
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADRā€™SSEVERITY AND SERIOUSNESS ASSESSMENT OF ADRā€™S
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADRā€™S
Ā 

Similar to Detection, reporting and monitoring of ad rs final ppt

MHRA Yellow Card Scheme
MHRA Yellow Card SchemeMHRA Yellow Card Scheme
MHRA Yellow Card Scheme
The QCCP
Ā 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
Akhil Joseph
Ā 
Adverse drug reactions
Adverse drug reactionsAdverse drug reactions
Adverse drug reactions
government medical college nagpur
Ā 
Ashutosh pharmacovigilance
Ashutosh pharmacovigilance Ashutosh pharmacovigilance
Ashutosh pharmacovigilance ASHUTOSH MISHRA
Ā 
Adverse Drug Reaction and Drug Interaction_PHARMACY PRACTICE
Adverse Drug Reaction and Drug Interaction_PHARMACY PRACTICEAdverse Drug Reaction and Drug Interaction_PHARMACY PRACTICE
Adverse Drug Reaction and Drug Interaction_PHARMACY PRACTICE
rishi2789
Ā 
Pharmacovigilance AN
Pharmacovigilance ANPharmacovigilance AN
Pharmacovigilance AN
Ahmed Nouri
Ā 
06 CHAPTER.pptx
06 CHAPTER.pptx06 CHAPTER.pptx
06 CHAPTER.pptx
Anusha Are
Ā 
pharmacovigilance- clinical pharmacy pharm-D
pharmacovigilance- clinical pharmacy pharm-Dpharmacovigilance- clinical pharmacy pharm-D
pharmacovigilance- clinical pharmacy pharm-D
Anusha Are
Ā 
Adverse drug reaction
Adverse drug reactionAdverse drug reaction
Adverse drug reaction
Zumar Mushtaq
Ā 
Adverse drug reactions
Adverse drug reactionsAdverse drug reactions
Adverse drug reactions
krishna prasad dahal
Ā 
Unit 4 pharmacovigilance (6hrs) march 13 2021
Unit 4 pharmacovigilance (6hrs) march 13 2021Unit 4 pharmacovigilance (6hrs) march 13 2021
Unit 4 pharmacovigilance (6hrs) march 13 2021
University of Gondar
Ā 
Adverse Drug reaction ppt
Adverse Drug reaction ppt Adverse Drug reaction ppt
Adverse Drug reaction ppt
ShikhaSachde
Ā 
ADR SEMINAR.pptx
ADR SEMINAR.pptxADR SEMINAR.pptx
Adverse Drug Reaction.pptx
Adverse Drug Reaction.pptxAdverse Drug Reaction.pptx
Adverse Drug Reaction.pptx
Bimal Magar
Ā 
DJ- ADR - 08.09.2021.pptx
DJ- ADR - 08.09.2021.pptxDJ- ADR - 08.09.2021.pptx
DJ- ADR - 08.09.2021.pptx
MuskanAslam
Ā 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
PharmacologyMGM
Ā 
Adverse Drug Reactions
Adverse Drug ReactionsAdverse Drug Reactions
Adverse Drug ReactionsBADAR UDDIN UMAR
Ā 
ADVERSE DRUG REACTIONS_LASUCOM LECTURE.ppt
ADVERSE DRUG REACTIONS_LASUCOM LECTURE.pptADVERSE DRUG REACTIONS_LASUCOM LECTURE.ppt
ADVERSE DRUG REACTIONS_LASUCOM LECTURE.ppt
MautonSamuel1
Ā 
Polypharmacy in the elderly
Polypharmacy in the elderlyPolypharmacy in the elderly
Polypharmacy in the elderlyMarc Evans Abat
Ā 
Adverse-Drug-Reactions-Patient-Level-by-Prof-Jamie-Coleman.pptx
Adverse-Drug-Reactions-Patient-Level-by-Prof-Jamie-Coleman.pptxAdverse-Drug-Reactions-Patient-Level-by-Prof-Jamie-Coleman.pptx
Adverse-Drug-Reactions-Patient-Level-by-Prof-Jamie-Coleman.pptx
Deepali69
Ā 

Similar to Detection, reporting and monitoring of ad rs final ppt (20)

MHRA Yellow Card Scheme
MHRA Yellow Card SchemeMHRA Yellow Card Scheme
MHRA Yellow Card Scheme
Ā 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
Ā 
Adverse drug reactions
Adverse drug reactionsAdverse drug reactions
Adverse drug reactions
Ā 
Ashutosh pharmacovigilance
Ashutosh pharmacovigilance Ashutosh pharmacovigilance
Ashutosh pharmacovigilance
Ā 
Adverse Drug Reaction and Drug Interaction_PHARMACY PRACTICE
Adverse Drug Reaction and Drug Interaction_PHARMACY PRACTICEAdverse Drug Reaction and Drug Interaction_PHARMACY PRACTICE
Adverse Drug Reaction and Drug Interaction_PHARMACY PRACTICE
Ā 
Pharmacovigilance AN
Pharmacovigilance ANPharmacovigilance AN
Pharmacovigilance AN
Ā 
06 CHAPTER.pptx
06 CHAPTER.pptx06 CHAPTER.pptx
06 CHAPTER.pptx
Ā 
pharmacovigilance- clinical pharmacy pharm-D
pharmacovigilance- clinical pharmacy pharm-Dpharmacovigilance- clinical pharmacy pharm-D
pharmacovigilance- clinical pharmacy pharm-D
Ā 
Adverse drug reaction
Adverse drug reactionAdverse drug reaction
Adverse drug reaction
Ā 
Adverse drug reactions
Adverse drug reactionsAdverse drug reactions
Adverse drug reactions
Ā 
Unit 4 pharmacovigilance (6hrs) march 13 2021
Unit 4 pharmacovigilance (6hrs) march 13 2021Unit 4 pharmacovigilance (6hrs) march 13 2021
Unit 4 pharmacovigilance (6hrs) march 13 2021
Ā 
Adverse Drug reaction ppt
Adverse Drug reaction ppt Adverse Drug reaction ppt
Adverse Drug reaction ppt
Ā 
ADR SEMINAR.pptx
ADR SEMINAR.pptxADR SEMINAR.pptx
ADR SEMINAR.pptx
Ā 
Adverse Drug Reaction.pptx
Adverse Drug Reaction.pptxAdverse Drug Reaction.pptx
Adverse Drug Reaction.pptx
Ā 
DJ- ADR - 08.09.2021.pptx
DJ- ADR - 08.09.2021.pptxDJ- ADR - 08.09.2021.pptx
DJ- ADR - 08.09.2021.pptx
Ā 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
Ā 
Adverse Drug Reactions
Adverse Drug ReactionsAdverse Drug Reactions
Adverse Drug Reactions
Ā 
ADVERSE DRUG REACTIONS_LASUCOM LECTURE.ppt
ADVERSE DRUG REACTIONS_LASUCOM LECTURE.pptADVERSE DRUG REACTIONS_LASUCOM LECTURE.ppt
ADVERSE DRUG REACTIONS_LASUCOM LECTURE.ppt
Ā 
Polypharmacy in the elderly
Polypharmacy in the elderlyPolypharmacy in the elderly
Polypharmacy in the elderly
Ā 
Adverse-Drug-Reactions-Patient-Level-by-Prof-Jamie-Coleman.pptx
Adverse-Drug-Reactions-Patient-Level-by-Prof-Jamie-Coleman.pptxAdverse-Drug-Reactions-Patient-Level-by-Prof-Jamie-Coleman.pptx
Adverse-Drug-Reactions-Patient-Level-by-Prof-Jamie-Coleman.pptx
Ā 

More from Sabeena Choudhary

HIDAC.pptx
HIDAC.pptxHIDAC.pptx
HIDAC.pptx
Sabeena Choudhary
Ā 
Drug dev approval
Drug dev approvalDrug dev approval
Drug dev approval
Sabeena Choudhary
Ā 
Role of olaparib in breast and ovarian cancers
Role of olaparib in breast and ovarian cancersRole of olaparib in breast and ovarian cancers
Role of olaparib in breast and ovarian cancers
Sabeena Choudhary
Ā 
RECIST
RECISTRECIST
Response assessment lymphomas
Response assessment lymphomasResponse assessment lymphomas
Response assessment lymphomas
Sabeena Choudhary
Ā 
Lymphoma staging and response evolution with current recommendations (2)
Lymphoma staging and response evolution with current recommendations (2)Lymphoma staging and response evolution with current recommendations (2)
Lymphoma staging and response evolution with current recommendations (2)
Sabeena Choudhary
Ā 
Part 2 response in lymphomas
Part 2 response in lymphomasPart 2 response in lymphomas
Part 2 response in lymphomas
Sabeena Choudhary
Ā 
lymphoma response
 lymphoma response lymphoma response
lymphoma response
Sabeena Choudhary
Ā 
phases of a clinical trial and accelerated drug
 phases of a clinical trial and accelerated drug phases of a clinical trial and accelerated drug
phases of a clinical trial and accelerated drug
Sabeena Choudhary
Ā 

More from Sabeena Choudhary (9)

HIDAC.pptx
HIDAC.pptxHIDAC.pptx
HIDAC.pptx
Ā 
Drug dev approval
Drug dev approvalDrug dev approval
Drug dev approval
Ā 
Role of olaparib in breast and ovarian cancers
Role of olaparib in breast and ovarian cancersRole of olaparib in breast and ovarian cancers
Role of olaparib in breast and ovarian cancers
Ā 
RECIST
RECISTRECIST
RECIST
Ā 
Response assessment lymphomas
Response assessment lymphomasResponse assessment lymphomas
Response assessment lymphomas
Ā 
Lymphoma staging and response evolution with current recommendations (2)
Lymphoma staging and response evolution with current recommendations (2)Lymphoma staging and response evolution with current recommendations (2)
Lymphoma staging and response evolution with current recommendations (2)
Ā 
Part 2 response in lymphomas
Part 2 response in lymphomasPart 2 response in lymphomas
Part 2 response in lymphomas
Ā 
lymphoma response
 lymphoma response lymphoma response
lymphoma response
Ā 
phases of a clinical trial and accelerated drug
 phases of a clinical trial and accelerated drug phases of a clinical trial and accelerated drug
phases of a clinical trial and accelerated drug
Ā 

Recently uploaded

Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
RaedMohamed3
Ā 
The geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideasThe geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideas
GeoBlogs
Ā 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
Celine George
Ā 
Home assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdfHome assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdf
Tamralipta Mahavidyalaya
Ā 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
siemaillard
Ā 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
Jisc
Ā 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
camakaiclarkmusic
Ā 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
MysoreMuleSoftMeetup
Ā 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
heathfieldcps1
Ā 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
DeeptiGupta154
Ā 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
Thiyagu K
Ā 
The Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdfThe Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdf
kaushalkr1407
Ā 
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdfAdversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Po-Chuan Chen
Ā 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
beazzy04
Ā 
Polish students' mobility in the Czech Republic
Polish students' mobility in the Czech RepublicPolish students' mobility in the Czech Republic
Polish students' mobility in the Czech Republic
Anna Sz.
Ā 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
vaibhavrinwa19
Ā 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
Ashokrao Mane college of Pharmacy Peth-Vadgaon
Ā 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
CarlosHernanMontoyab2
Ā 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
EduSkills OECD
Ā 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
EverAndrsGuerraGuerr
Ā 

Recently uploaded (20)

Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
Ā 
The geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideasThe geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideas
Ā 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
Ā 
Home assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdfHome assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdf
Ā 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
Ā 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
Ā 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
Ā 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Ā 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
Ā 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
Ā 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
Ā 
The Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdfThe Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdf
Ā 
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdfAdversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Ā 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
Ā 
Polish students' mobility in the Czech Republic
Polish students' mobility in the Czech RepublicPolish students' mobility in the Czech Republic
Polish students' mobility in the Czech Republic
Ā 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
Ā 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
Ā 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
Ā 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
Ā 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
Ā 

Detection, reporting and monitoring of ad rs final ppt

  • 1. DETECTION, REPORTING AND MONITORING OF ADRs DR SABEENA K CHOUDHARY
  • 2. Overview ā€¢ ADRs ( types and importance) ā€¢ ADR Reporting (Pharmacovigilance): what when and how to report these ADRs
  • 3.
  • 4.
  • 5.
  • 7. ā€¢ Everytime we give a drug we take a risk ā€¢ Public and professional concern about these matters first arose in the late 19th century. ā€¢ In 1922, there was an enquiry into the JAUNDICE associated with the use of SALVARSAN, an organic arsenical used in the treatment of Syphillis.
  • 8. ā€¢ In 1937 in USA, 107 people died from taking an Elixir Of Sulfalinamide that contained the Solvent Di-ethylene Glycol This led to establishment of FOOD AND DRUG ADMINISTRATION (FDA), which was given the task of enquiring into the safety of new drugs before allowing them to be marketed
  • 9.
  • 10. ā€¢ In 1961, it was reported in West Germany that there was an outbreak of PHOCOMELIA (hypoplastic and aplastic limb deformities) in the new born babies.
  • 11. ā€¢ The Thalidomide Incident led to development of a much more sophisticated approach to preclinical testing & clinical evaluation of drugs before marketing, & greatly increased awareness of adverse effect of drugs and methods of detecting them.
  • 12. Importance of ADRā€™S in Therapeutics
  • 13. Adverse event ā€¢ Any untoward medical occurrence that may present during treatment with a pharmaceutical product ā€¢ But doesnā€™t have a causal relation with this Rx
  • 14. Adverse drug reaction ā€¢ Response which is noxious and unintended , which occurs at doses normally used in humans for the Px, Dx or therapy of the disease or for modification of physiological function ā€¢ All ADR are AE but not vice versa
  • 15. Side effect ā€¢ Any unintended effect (unwanted but unavoidable of a product occurring at normal dose which is related to the pharmacological properties of the drug ) Unwanted but often unavoidable pharmacodynamic effects of a drug at therapeutic dosesā€ As Extension of therapeutic effect Atropine - dry mouth As distinctly different effect Promethazine ā€“ Sedation. Side effect exploited for therapeutic use Codeine ā€“ Diarrhoea
  • 16. ADR vs side effect
  • 17.
  • 18.
  • 19. Serious ADR ā€¢ Death ā€¢ Life threatening condition ā€¢ Requires inpatient hospitalization/ prolongation ā€¢ Persistent disability/incapacity ā€¢ Congenital abnormality
  • 20. Incidence ļƒ˜Hospital in-patients:10-20% ļƒ˜Deaths in hospital in-patients: 0.3-3% ļƒ˜Hospital admissions: 0.3-5%
  • 22. ā€¢ Ever-increasing number of new drugs in the market ā€¢ Number of drugs prescribed are high ā€¢ Medication errors ā€¢ Lack of awareness of a system for reporting ADRā€™S
  • 23. Common causes ļ± Failing to take the correct dose at the correct times ļ±Overdosing ļ± Allergies to chemical components of the medicine ļ± Combining the medicine with alcohol ļ± Taking other drugs or preparations that interact with the medicine
  • 24. Factors affecting Adverse Drug Reactions
  • 25. ļ¶ Age ļ¶ Genetic influences ļ¶ Concurrent diseases (Renal, Liver, Cardiac) ļ¶ Previous allergies or adverse drug reactions ļ¶ Compliance with dosing regimen ļ¶ Total number of medications ļ¶ Misc. (diet, smoking, environmental exposure)
  • 27. Idiosyncracy ā€¢ Genetically determined abnormal reaction to the agent ā€¢ Interaction of the drug with the unique feature of the individual ā€¢ Produces uncharacteristic reaction
  • 29. Rawlins and Thompson classification -1991 Type A Predictable -More Common(80%) -Augmented normal response -Dose dependent -Hypo/Hyper response Type B Unpredictable -Less common (6-10%) -Abnormal/bizarre response -Dose Independent -Genetic/Immunological
  • 30. Type A Predictable -Low Mortality -d/t Pharmacological activity of drug -Rx : Dose Adjustment Eg., S/E, Toxic effect, Withdrawal effect Diarrhea due to antibiotics Type B Unpredictable -High Mortality -d/t Patient peculiarities -Rx : Withdrawal of drug Eg., Allergy, Idiosyncrasy Hypersensitivity to penicillin Types of ADRā€™s ā€“ Contdā€¦
  • 31. Type C (Chronic) - Reactions due to prolonged use of the Drug. e.g. HPA axis suppression by corticosteroids
  • 32. Type D (Delayed) ā€¢ Occuring years after the treatment ā€¢ Can be due to accumulation E.g : Teratogenisis
  • 33. Type E (End of use) ā€¢ Occur on withdrawal especially when drug is stopped abruptly E.g. ā€¢ Steroid withdrwal
  • 34. Type F (Failure of drug) ā€¢ Underdosing of medications ā€¢ Drug interactions Eg: OCP failure
  • 35. Type Mnemonic Example A Augmented Diarrohea due to antibiotics B Bizzare Hypersensitivity due to penicillin C Chronic Steroid decrease HPA axis D Delayed Teratogenicity, carcinogenesis E End of use Precipitation of MI by Ī² blocker withdrawal F Failure OCP failure Types of ADRā€™s in Brief:
  • 36. Mild No need of Rx, antidote or Hospitalization Moderate Requires drug change specific Rx, hospitalization Severe Potentially life threatening; permanent damage, and prolonged hospitalization. Lethal Directly or indirectly leads to death ADR GRADING
  • 38. Who can get an ADR? Anyone who takes medicine Differential diagnosis should include the possibility of an ADR if the patient is taking any form of medication
  • 39. If symptoms, ļƒ¼Appears soon after a new drug is started ļƒ¼Appears after an increase in dose ļƒ¼Disappears when the drug is stopped ļƒ¼Reappears when a drug is restarted When To Report :
  • 41. ā€¢ WHO international system(Uppsala monitoring centre, Sweden) ā€¢ US FDA "Med watch" ā€¢ UK "Yellow card system" ā€¢ PvPI under CDSCO, India
  • 42. ā€¢ ACTIVE SURVEILLANCE ā€¢ PASSIVE SURVEILLANCE
  • 43. ā€¢ SPONTANEOUS REPORTING SYSTEM : ā€¢ Communication by HCP/ consumers/ pharma company to NCC/CDSCO/AMC
  • 44. Why is ADR Monitoring Needed? ā€¢ Unreliability of pre-clinical studies ā€¢ Limitations of pre-marketing phases of clinical trial ā€¢ Aggressive marketing strategies of pharmaceutical companies
  • 45. Limitations of pre-marketing phases of clinical trial ā€¢ Conducted in strictly controlled conditions, in highly selected and limited number of patients ā€¢ Fails to detect rare and delayed ADRs ā€¢ Do not provide data ā€“ - In children, elderly patients, pregnant/lactating women - In patient suffering from other disease - In patient receiving other drugs - On interpopulation difference
  • 46. What to report ā€¢ All types of suspected ADRs irrespective of whether they r known / uk, serious or non serious , frequent or rare, and regardless of an established causal relationship ā€¢ Pharma meds and vaccines, drugs used in traditional meds , medical devices, contrast media ā€¢ Any AE
  • 47. ā€¢ Doctors ā€¢ Dentists ā€¢ Nurses ā€¢ Pharmacists Health care professionals ā€¢ Patients ā€¢ Consumers ā€¢ Relatives Others Who can report ??
  • 48. Problems in ADR reporting Patient Related (i) Cannot recognize ADR (ii) Recognize but do not report (iii) Illiteracy Health professional Related (i) Cannot recognize ADR (ii) Recognize but do not report due to - Lack of time - Hesitancy - Ignorance - Fear of litigation - Guilt ā€¢
  • 50.
  • 51.
  • 55. Causality Assessment ā€¢ Routine procedure in Pharmacovigilance ā€¢ Relationship of cause & effect ā€¢ Most outcomes : multiple interacting causes ā€¢ Aim : to define contribution due to drugs ā€¢ Problems: ADRs rarely specific Diagnostic tests usually absent Re challenge rarely ethically justified
  • 56. Causality Assessment Methods Algorithmic: Series of questions Answers are weighted Overall score determines causality category e.g. Naranjoā€™s scale Probalistic: Set of explicitly defined causality categories e.g. WHO UMC method
  • 57. Questions Yes No Donā€™t Know 1) Are there previous conclusive reports on this reaction? +1 0 0 2) Did the ADR appear after the suspected drug was administered? +2 -1 0 3) Did the ADR improve when the drug was discontinued? +1 0 0 4) Did the ADR appear with re-challenge? +2 -1 0 5) Are there alternative causes for the ADR? -1 +2 0 6) Did the reaction appear when placebo was given? -1 +1 0 7) Was the drug detected in blood at toxic levels? +1 0 0 8) Was the reaction more severe when the dose was increased, or less severe when the dose was decreased? +1 0 0 9) Did the patient have a similar reaction to the same or similar drug in any previous exposure? +1 0 0 10) Was the ADR confirmed by any objective evidence? +1 0 0
  • 58. The Naranjo Probability Scale The score :- ā‰„ 9 = Definite 5-8 = Probable 1-4 = Possible 0 = Doubtful
  • 59.
  • 61.
  • 62.
  • 63.
  • 64.
  • 65.
  • 66. Drugs restricted due to adverse reactions
  • 67. Drug Year Adverse Reaction Outcome Sulfanilamide 1937 Liver damage due to diethylene glycol Solvent changed; FDA established Thalidomide 1961 Congenital Malformations Withdrawn Chloramphenicol 1966 Blood Dyscrasias Uses restricted Benoxaprofan 1982 Liver damage Withdrawn Aspirin 1986 Reyeā€™s syndrome Uses restricted Flecainide 1989 Cardiac Arrhythmias Uses restricted Noscapine 1991 Gene toxicity Withdrawn Triazolam 1991 Psychiatric disorders Withdrawn
  • 68. Drug Year Adverse reaction Outcome Temafloxacin 1992 Various serious adverse effects Withdrawn Co-trimoxazole 1995 Serious allergic reactions Uses restricted Terfenadine 1997 Interactions (e.g. with grapefruit juice) Withdrawn from OTC sale Sotalol 1997 Cardiac arrhythmias Uses restricted Astemizole 1998 Interactions Withdrawn Cisapride 2000 Cardiac arrhythmias Withdrawn Cerivastatin 2001 Rhabdomylosis Withdrawn
  • 69. Drug Event Outcome Fenfluramine, Dexfenfluramine Heart valve disease, Pulmonary hypertension, Cardiac fibrosis Banned Sibutramine Heart attack , Stroke Banned Astemizole ,Terfinadine Arrhythmias Banned Rofecoxib ,Valdecoxib Myocardial infarction Banned Rosiglitazone MI, stroke,CHF,death Banned Cisapride QT interval prolongation- ventricular arrhythmias Banned Gatifloxacin Arrhythmias, Phototoxicity, Unpredictable hypoglycemia Banned Nimesulide (Paediatric) Fulminant hepatic failure Paediatric use -banned Phenylpropanolamine Hemorrhagic stroke Psychiatric disturbances Banned( Banned order under court stay)
  • 70. Take home messageā€¦ ā€¢ Every drug which has an effect has an adverse effect every time a drug is given risk is involved ā€¢ For rational use of drug not only its clinical indications are important but the knowledge of adverse effects as well ā€¢ Early detection of adverse effects and its proper management can be life saving in many situations ā€¢ ADR Reporting (Pharmacovigilance) plays a important role in the evolution and life history of a drug

Editor's Notes

  1. Analgesic /// peptic ulcer , kidney dx (unintended)
  2. To later on come to conclusion if this effect is more in a particular age group